Current treatment of hepatitis C-associated rheumatic diseases

Arthritis Research and Therapy

Volumn 14, Issue 3, 2012, Pages

  Ferri, Clodoveo ^a   Sebastiani, Marco ^a   Antonelli, Alessandro ^b   Colaci, Michele ^a   Manfredi, A ^a   Giuggioli, Dilia ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; COLCHICINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; METHYLPREDNISOLONE; PEGINTERFERON; RIBAVIRIN; RITUXIMAB; STEROID; TUMOR NECROSIS FACTOR INHIBITOR;

CLINICAL PRACTICE; COMORBIDITY; CRYOGLOBULINEMIA; DERMATOMYOSITIS; DISEASE SEVERITY; DRUG MEGADOSE; DRUG POTENTIATION; FIBROMYALGIA; HEPATITIS C; HUMAN; LOW DRUG DOSE; MOTOR NEUROPATHY; MYALGIA; NONHUMAN; OSTEOSCLEROSIS; PERIPHERAL NEUROPATHY; PLASMAPHERESIS; POLYARTERITIS NODOSA; POLYARTHRITIS; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; THYROIDITIS; UNSPECIFIED SIDE EFFECT; VASCULITIS;

HEPATITIS C; HUMANS; RHEUMATIC DISEASES;

EID: 84862755811     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3865     Document Type: Review

References (49)

1. Ferri C. Mixed cryoglobulinemia. Orphanet J Rare Dis 2008, 3:25. 10.1186/1750-1172-3-25, 2569912, 18796155.
2. Dammacco F, Sansonno D, Piccoli C, Racanelli V, D'Amore FP, Lauletta G. The lymphoid system in hepatitis C virus infection: autoimmunity, mixed cryoglobulinemia, and overt B-cell malignancy. Semin Liver Dis 2000, 20:143-157. 10.1055/s-2000-9613, 10946420.
3. Ferri C, Cacoub P, Mascia MT, Saadoun D. Cryoglobulinemia and systemic manifestations of hepatitis C virus. EULAR Compendium on Rheumatic Diseases 2009, 616-635. London, BMJ Publishing Group Ltd.
4. Ferri C, Antonelli A, Mascia MT, Sebastiani M, Fallahi P, Ferrari D, Pileri SA, Zignego AL. HCV-related autoimmune and neoplastic disorders: the HCV syndrome. Dig Liver Dis 2007, (39 Suppl 1):S13-21.
5. Zignego AL, Macchia D, Monti M, Thiers V, Mazzetti M, Foschi M, Maggi E, Romagnani S, Gentilini P, Brechot C. Infection of peripheral mononuclear blood cells by hepatitis C virus. J Hepatol 1992, 15:382-386.
6. Lunel F, Musset L, Cacoub P, Frangeul L, Cresta P, Perrin M, Grippon P, Hoang C, Valla D, Piette JC. Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. Gastroenterology 1994, 106:1291-1300.
7. Zignego AL, Ferri C, Giannelli F, Giannini C, Caini P, Monti M, Marrocchi EM, Di Pietro E, La Villa G, Laffi G, Gentilini P. Prevalence of BCL-2 rearrangement in hepatitis C virus-related mixed cryoglobulinemia with or without complicating B-cell lymphoma. Ann Intern Med 2002, 137:571-580.
8. Buskila D. Hepatitis C-associated rheumatic disorders. Rheum Dis Clin North Am 2009, 35:111-123. 10.1016/j.rdc.2009.03.005, 19481000.
9. Lormeau C, Falgarone G, Roulot D, Boissier MC. Rheumatologic manifestations of chronic hepatitis C infection. Joint Bone Spine 2006, 73:633-638. 10.1016/j.jbspin.2006.05.005, 17056293.
10. De Vita S, Soldano F, Isola M, Monti G, Gabrielli A, Tzioufas A, Ferri C, Ferraccioli GF, Quartuccio L, Corazza L, De Marchi G, Casals MR, Voulgarelis M, Lenzi M, Saccardo F, Fraticelli P, Mascia MT, Sansonno D, Cacoub P, Tomsic M, Tavoni A, Pietrogrande M, Zignego AL, Scarpato S, Mazzaro C, Pioltelli P, Steinfeld S, Lamprecht P, Bombardieri S, Galli M. Preliminary classification criteria for the cryoglobulinaemic vasculitis. Ann Rheum Dis 2011, 70:1183-1190. 10.1136/ard.2011.150755, 3103668, 21571735.
11. Monti G, Galli M, Invernizzi F, Pioltelli P, Saccardo F, Monteverde A, Pietrogrande M, Renoldi P, Bombardieri S, Bordin G, Candela M, Ferri C, Gabrielli A, Mazzaro C, Migliaresi S, Mussini C, Ossi E, Quintiliani L, Tirri G, Vacca A, . GISC, Italian Group for the Study of Cryoglobulinaemias Cryoglobulinaemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. QJM 1995, 88:115-126. GISC, Italian Group for the Study of Cryoglobulinaemias.
12. Zuckerman E, Keren D, Slobodin G, Rosner I, Rozenbaum M, Toubi E, Sabo E, Tsykounov I, Naschitz JE, Yeshurun D. Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha. J Rheumatol 2000, 27:2172-2178.
13. Mazzaro C, Zora F, Caizzi M, Donada C, Di Gennaro G, Dal Maso K, Carniello G, Virgolini L, Tirelli U, Pozzato G. Treatment with peg interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. J Hepatol 2005, 42:632-638. 10.1016/j.jhep.2004.10.031, 15826710.
14. Lidove O, Cacoub P, Hausfater P, Wechsler B, Frances C, Leger JM, Piette JC. Cryoglobulinemia and hepatitis C: worsening of peripheral neuropathy after interferon alpha treatment. Gastroenterol Clin Biol 1999, 23:403-406.
15. Toussaint NC, Maman Y, Kohlbacher O, Louzoun Y. Universal peptide vaccines - Optimal peptide vaccine design based on viral sequence conservation. Vaccine 2011, 29:8745-8753. 10.1016/j.vaccine.2011.07.132, 21875632.
16. Galeazzi M, Bellisai F, Manganelli S, Morozzi G, Sebastiani GD. Cyclosporine A for the treatment of autoimmune disorders in HCV infected patients. Autoimmun Rev 2006, 5:493-498. 10.1016/j.autrev.2006.01.002, 16920576.
17. Zein NN, . for the Etanercept Study Group Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005, 42:315-322. 10.1016/j.jhep.2004.11.025, 15791697, for the Etanercept Study Group.
18. Ferri C, Cacoub P, Mazzaro C, Roccatello D, Scaini P, Sebastiani M, Tavoni A, Zignego AL, De Vita S. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: Results of multicenter cohort study and review of the literature. Autoimmun Rev 2011, 11:48-55. 10.1016/j.autrev.2011.07.005, 21821153.
19. Petrarca A, Rigacci L, Caini P, Colagrande S, Romagnoli P, Vizzutti F, Arena U, Giannini C, Monti M, Montalto P, Matucci-Cerinic M, Bosi A, Laffi G, Zignego AL. Safety and efficacy of rituximab in patients with hepatitis C virus related mixed cryoglobulinemia and severe liver disease. Blood 2010, 116:335-342. 10.1182/blood-2009-11-253948, 20308604.
20. De Vita S, Quartuccio L, Isola M, Mazzaro C, Scaini P, Lenzi M, Campanini M, Naclerio C, Tavoni A, Pietrogrande M, Ferri C, Mascia MT, Masolini P, Zabotti A, Maset M, Roccatello D, Zignego AL, Pioltelli P, Gabrielli A, Filippini D, Perrella O, Migliaresi S, Galli M, Bombardieri S, Monti G. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 2012, 64:843-853. 10.1002/art.34331, 22147661.
21. Ferri C, Pietrogrande M, Cecchetti C, Tavoni A, Cefalo A, Buzzetti G, Vitali C, Bombardieri S. Low-antigen-content diet in the treatment of mixed cryoglobulinemia patients. Am J Med 1989, 87:519-524. 10.1016/S0002-9343(89)80607-2, 2816967.
22. Stefanutti C, Di Giacomo S, Mareri M, De Lorenzo F, D'Alessandri G, Angelico F, Bucci A, Musca A, Mammarella A. Immunoadsorption apheresis (Selesorb) in the treatment of chronic hepatitis C virus-related type 2 mixed cryoglobulinemia. Transfus Apher Sci 2003, 28:207-214. 10.1016/S1473-0502(03)00055-7, 12725944.
23. Falanga V. Wound bed preparation: future approaches. Ostomy Wound Manage 2003, (49 Suppl 5):30-33.
24. Frykberg RG, Driver VR, Carman D, Lucero B, Borris-Hale C, Fylling CP, Rappl LM, Clausen PA. Chronic wounds treated with a physiologically relevant concentration of platelet-rich plasma gel: a prospective case series. Ostomy Wound Manage 2010, 56:36-44.
25. Saadoun D, Resche Rigon M, Sene D, Terrier B, Karras A, Perard L, Schoindre Y, Coppere B, Blanc F, Musset L, Piette JC, Rosenzwajg M, Cacoub P. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood 2010, 116:326-334. 10.1182/blood-2009-10-248518, 20439619.
26. Dammacco F, Tucci FA, Lauletta G, Gatti P, De Re V, Conteduca V, Sansonno S, Russi S, Mariggio MA, Chironna M, Sansonno D. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood 2010, 116:343-353. 10.1182/blood-2009-10-245878, 20308602.
27. Pietrogrande M, De Vita S, Zignego AL, Pioltelli P, Sansonno D, Sollima S, Atzeni F, Saccardo F, Quartuccio L, Bruno S, Bruno R, Campanini M, Candela M, Castelnovo L, Gabrielli A, Gaeta GB, Marson P, Mascia MT, Mazzaro C, Mazzotta F, Meroni P, Montecucco C, Ossi E, Piccinino F, Prati D, Puoti M, Riboldi P, Riva A, Roccatello D, Sagnelli E, et al. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virusinfected patients. Autoimmun Rev 2011, 10:444-454. 10.1016/j.autrev.2011.01.008, 21303705.
28. Vitali C. Immunopathologic differences of Sjögren's syndrome versus sicca syndrome in HCV and HIV infection. Arthritis Res Ther 2011, 13:233. 10.1186/ar3361, 3239338, 21888688.
29. Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, Piette JC, Opolon P. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Arthritis Rheum 1999, 42:2204-2212. 10.1002/1529-0131(199910)42:10<2204::AID-ANR24>3.0.CO;2-D, 10524695.
30. Toussirot E, Le Huede G, Mougin C, Balblanc JC, Bettinger D, Wendling D. Presence of hepatitis C virus RNA in the salivary glands of patients with Sjogren's syndrome and hepatitis C virus infection. J Rheumatol 2002, 29:2382-2385.
31. Ioannidis JPA, Vassiliou VA, Moutsopoulos HM. Long term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome. Arthritis Rheum 2002, 46:741-747. 10.1002/art.10221, 11920410.
32. Doffoël-Hantz V, Loustaud-Ratti V, Ramos-Casals M, Alain S, Bezanahary H, Liozon E, Fauchais AL, Vidal E. Evolution of Sjögren syndrome associated with hepatitis C virus when chronic hepatitis C is treated by interferon or the association of interferon and ribavirin. Rev Med Interne 2005, 26:88-94. 10.1016/j.revmed.2004.10.020, 15710254.
33. Bombardieri M, Alessandri C, Labbadia G, Iannuccelli C, Carlucci F, Riccieri V, Paoletti V, Valesini G. Role of anti-cyclic citrullinated peptide antibodies in discriminating patients with rheumatoid arthritis from patients with chronic hepatitis C infection-associated polyarticular involvement. Arthritis Res Ther 2004, 6:137-141. 10.1186/ar1041, 15059277.
34. Palazzi C, Olivieri I, Cacciatore P, Pennese E, D'Amico E. Difficulties in the differential diagnosis between primitive rheumatic diseases and hepatitis C virus-related disorders. Clin Exp Rheumatol 2005, 23:2-6.
35. Ferri C, Govoni M, Calabrese L. The A, B, Cs of viral hepatitis in the biologic era. Curr Opin Rheumatol 2010, 22:443-450. 10.1097/BOR.0b013e328338f6df, 20386453.
36. Ferri C, Ferraccioli G, Ferrari D, Galeazzi M, Lapadula G, Montecucco C, Triolo G, Valentini G, Valesini G, . GISEA Group Safety of anti-tumor necrosis factor-alfa therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol 2008, 35:1944-1949. GISEA Group.
37. Villareal DT, Murphy WA, Teitelbaum SL, Arens MQ, Whyte MP. Painful diffuse osteosclerosis after intravenous drug abuse. Am J Med 1992, 93:371-381. 10.1016/0002-9343(92)90165-8, 1329508.
38. Manganelli P, Giuliani N, Fietta P, Mancini C, Lazzaretti M, Pollini A, Quaini F, Pedrazzoni M. OPG/RANKL system imbalance in a case of hepatitis C-associated osteosclerosis: the pathogenetic key?. Clin Rheumatol 2005, 24:296-300. 10.1007/s10067-004-1031-3, 15583970.
39. Tanaka T, Oki S, Muro S, Tanaka K, Hashimoto J. A case of hepatitis C-associated osteosclerosis in an elderly Japanese man. Endocr J 2006, 53:393-399. 10.1507/endocrj.K04-131, 16717394.
40. Javier RM, de Vernejoul MC, Afif N, Kuntz JL, Sibilia J. Skeletal recovery from hepatitis C-associated osteosclerosis (HCAO) following antiviral treatment. Joint Bone Spine 2011, 78:409-411. 10.1016/j.jbspin.2011.02.016, 21498104.
41. Ito H, Ito H, Nagano M, Nakano S, Shigeyoshi Y, Kusaka H. In situ identification of hepatitis C virus RNA in muscle. Neurology 2005, 64:1073-1075. 10.1212/01.WNL.0000154605.02737.FE, 15781833.
42. Kozanoglu E, Canataroglu A, Abayli B, Colakoglu S, Goncu K. Fibromyalgia syndrome in patients with hepatitis C infection. Rheumatol Int 2003, 23:248-251. 10.1007/s00296-003-0290-7, 14504918.
43. Narváez J, Nolla JM, Valverde-Garcia J. Lack of association of fibromyalgia with hepatitis C virus infection. J Rheumatol 2005, 32:1118-1121.
44. Fiore G, Giacovazzo F, Giacovazzo M. HCV and dermatomyositis: report of 5 cases of dermatomyositis in patients with HCV infection. Riv Eur Sci Med Farmacol 1996, 18:197-201.
45. Aouba A, Georgin-Lavialle S, Terrier B, Guillevin L, Authier FJ. Anti-PL7 antisynthetase syndrome under interferon therapy. Joint Bone Spine 2011, 78:94-97. 10.1016/j.jbspin.2010.07.012, 20851661.
46. Saadoun D, Terrier B, Semoun O, Sene D, Maisonobe T, Musset L, Amoura Z, Rigon MR, Cacoub P. Hepatitis C virus-associated polyarteritis nodosa. Arthritis Care Res 2011, 63:427-435.
47. Terrier B, Cacoub P. Hepatitis B virus, extrahepatic immunologic manifestations and risk of viral reactivation. Rev Med Interne 2011, 32:622-627. 10.1016/j.revmed.2010.08.013, 20870315.
48. Erkek E, Ayaslioglu E. Hepatitis C virus and Behcet's disease. J Gastroenterol Hepatol 2005, 20:1309. 10.1111/j.1440-1746.2005.03874.x, 16048588.
49. Ramos-Casals M, Muñoz S, Medina F, Jara LJ, Rosas J, Calvo-Alen J, Brito-Zerón P, Forns X, Sánchez-Tapias JM, . HISPAMEC Study Group Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry). J Rheumatol 2009, 36:1442-1448. 10.3899/jrheum.080874, 19369460, HISPAMEC Study Group.